Rechercher des études
Résultats de recherche
Cancer continues to have the dubious honor of being the leading cause of premature mortality in Canada. The good news is, advances in early detection and cancer treatments are extending the lives of those diagnosed with the disease. However, as more people are living longer, the impact of the therapies used to treat the disease are becoming increasingly apparent. Ranging from the physiological to psychological, cancer survivors are often confronted with substantial, disabling, and life-threatening consequences. The benefits of physical activity (all movement) and exercise more specifically have long been established as a means of prevention and treatment of chronic disease. Several recent reviews and meta-analyses have demonstrated that exercise is a safe and effective means of preventing and improving a multitude of physical and psychological treatment and disease-related sequelae across the cancer trajectory. For example, we know that cancer survivors who exercise not only have a reduced risk of disease recurrence and cancer mortality, but also have reduced acute/late effects of their cancer and/or its treatment such as anxiety, depression, and cancer-related pain. Regrettably, despite our substantial knowledge base, the majority of cancer survivors are not sufficiently active to realize these benefits over the long-term. Moreover, even with the development of evidence-based guidelines, exercise has not yet been widely implemented as a standard of care in the oncology setting largely due to a lack of resources, exercise expertise, and awareness of benefits. Continuing to provide cancer care with little guidance and understanding of the benefits of exercise places cancer survivors at an increased risk for recurrence, late effects, and/or onset of additional co-morbidities, and premature mortality. Therefore, it is important to consider best practices that will optimize and improve quality of survival. Building on the ongoing work of our Alberta-based colleagues and the Alberta Cancer Exercise (ACE) Program (an evidence-based clinic-to-community cancer exercise model), Activating Cancer Communities through an Exercise Strategy for Survivors (ACCESS) is designed to bridge the gap between research and practice and in doing so, lessen the impact of a cancer diagnosis and its treatment(s) on the physical and psychological well-being of cancer survivors.
Conditions:
CancerEmplacement:
- QEII Health Sciences Centre (Dickson Bldg), Halifax, Nova Scotia, Canada
Sexe:
ALLÂges:
Over 18Injection of Botox into the bladder is a procedure used to treat neurogenic overactive bladder at the Dianne and Irving Kipnes Urology Centre in the Kaye Edmonton Clinic. A common complication following bladder Botox is bladder infection. There are no well-studied preventative antibiotics given at the time of bladder Botox for the reduction of post-operative bladder infection. We are proposing a research study that will randomize participants into two groups - one receiving antibiotics and the other receiving placebo pills following bladder Botox. The main goal of our study is to determine if preventative antibiotics at the time of bladder Botox injection reduces post-operative bladder infection. It will provide a valuable learning opportunity for a trainee starting their academic career through working closely with established researchers across two disciplines. We hope the results of our study can ultimately be used to improve outcomes and safety for a common Urologic procedure. In addition, findings from our study could help reduce unnecessary use of antibiotics resulting in cost savings in the health care system and reduction in the risk of antibiotic resistance.
Conditions:
Neurogenic Bladder | Post-operative Urinary Tract InfectionsEmplacement:
- University of Alberta, Edmonton, Alberta, Canada
Sexe:
ALLÂges:
18 - 100Coronary revascularization, such as heart bypass surgery (CABG) and percutaneous coronary intervention (PCI \[inserting a stent to open up blood vessels\]) improve survival for people with coronary artery disease. Yet, many patients suffer from poor physical and mental health after coronary revascularization. Traditional cardiac rehabilitation involving moderate-to-vigorous intensity continuous training (MICT) improves physical and mental health. However, alternative exercise programs, such as high-intensity interval training (HIIT) and Nordic walking may provide superior benefits. Nordic walking is like Nordic skiing but uses specifically designed poles for walking. Nordic walking involved core, upper and lower body muscles, resulting in greater energy expenditure while reducing loading stress at the knee. To date, HIIT used in cardiac rehabilitation settings has focused on lower body (e.g., leg cycling). The investigators are not aware of HIIT protocols that target both upper and lower body at the same time. An exercise program that combines HIIT and Nordic walking (HIIT-NoW) may offer an alternative time-efficient whole-body exercise to improve physical and mental health. This study will test if HIIT-NoW can be an alternative exercise option to improve physical and mental health in patients with coronary artery disease.
Conditions:
Coronary Artery DiseaseEmplacement:
- University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Sexe:
ALLÂges:
Over 40Background: Chronic Obstructive Pulmonary (COPD) patients are the paradigm of the chronic complex patient. Their follow up can sometimes be difficult and challenging (1). There are patients with recurrent exacerbations that put an enormous burden on health care resources (2). They also have multiple comorbidities (3) that can sometimes make their management difficult. In an attempt to coordinate all these efforts KGH, HDH and Providence Care have numerous essential resources to take care of COPD patients like the nurse navigators, nurse practitioners and the pulmonary rehabilitation program. These programs provide an excellent support to the clinical activity of Respirologists and other health care providers. Rationale: The main rationale for the development of the Kingston COPD cohort is to translate that highly demanding clinical activity in a teaching and research oriented activity that could be used by clinicians, medical students, residents and fellows. Having a guideline complained established protocol in COPD patients that are usually follow at KGH and HDH could help in not only in unified the way COPD patients are seeing (preserving the importance of the personalized approach) but most importantly established a multidimensional (clinical, physiological, radiological, laboratory) database. This could help know not only the results of our clinical activity but also have a long term (\>5yrs) database for clinical research projects in collaboration with national and international research groups. Therefore this proposal is important because it will help translate our busy daily clinical work in a highly productive teaching and research activity.
Conditions:
COPD | EmphysemaEmplacement:
- KHSC, Kingston, Ontario, Canada
Sexe:
ALLÂges:
40 - 85To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Conditions:
Relapsing Multiple SclerosisEmplacement:
- Novartis Investigative Site, Halifax, Nova Scotia, Canada
- Novartis Investigative Site, Montreal, Quebec, Canada
- Novartis Investigative Site, Burnaby, British Columbia, Canada
- Novartis Investigative Site, Levis, Quebec, Canada
- Novartis Investigative Site, Edmonton, Alberta, Canada
- Novartis Investigative Site, Greenfield Park, Quebec, Canada
- Novartis Investigative Site, Ottawa, Ontario, Canada
- Novartis Investigative Site, St Jerome, Quebec, Canada
Sexe:
ALLÂges:
18 - 55The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25 years as a comparator cohort.
Conditions:
CytomegalovirusEmplacement:
- CARe Clinic, Red Deer, Alberta, Canada
- Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada
- Bluewater Clinical Research Group, Sarnia, Ontario, Canada
- ALTA Clinical Research Inc, Edmonton, Alberta, Canada
- M.A.G.I.C. Clinic Ltd. Metabolics and Genetics in Calgary, Calgary, Alberta, Canada
- Hamilton Medical Research Group, Hamilton, Ontario, Canada
- Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada
Sexe:
ALLÂges:
9 - 25Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.
Conditions:
Carcinoma | Non-Small-Cell LungEmplacement:
- Research Site, Mississauga, Ontario, Canada
- Research Site, Montreal, Quebec, Canada
- Research Site, Calgary, Alberta, Canada
- Research Site, Montreal, Quebec, Canada
- Research Site, Toronto, Ontario, Canada
- Research Site, Toronto, Ontario, Canada
Sexe:
ALLÂges:
18 - 130The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.
Conditions:
Metastatic Castrate-sensitive Prostate CancerEmplacement:
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
- Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
- Southern Alberta Institute of Urology / Prostate Cancer Centre, Calgary, Alberta, Canada
Sexe:
MALEÂges:
Over 18Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scope (cystoscopy). Millions of cystoscopies are performed every year worldwide for patients presenting with hematuria, but only 10% result in a cancer diagnosis. The UROSCOUT-1 trial is a prospective multicenter observational study that explores the potential of urine tumor DNA (utDNA) testing to replace a significant portion of cystoscopies in the diagnostic setting for hematuria or other reasons to rule out urothelial cancer. The goal is to enhance patient quality of life, reduce healthcare costs, and address increased workloads in urology centers. Sample collection will be conducted by mail, and the samples will be analyzed in a blinded manner, without knowledge of which patients are diagnosed with cancer. Random subsampling will be applied to cancer-negative patients to achieve an approximate 1:1 ratio between cancer-positive and -negative patients.
Conditions:
Urothelial CarcinomaEmplacement:
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
Sexe:
ALLÂges:
18 - 100The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Conditions:
Relapsed or Refractory Multiple MyelomaEmplacement:
- Cross Cancer Institute, Edmonton, Alberta, Canada
- Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada